Astera Labs (ALAB) CEO’s trust sells 157,500 shares but keeps large stake

Rhea-AI Filing Summary

Astera Labs, Inc. director and Chief Executive Officer Mohan Jitendra reported that a living trust associated with him sold 157,500 shares of common stock in open-market transactions on March 17, 2026, under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.

The sales were executed indirectly through the living trust at weighted-average prices generally between about $125 and $135 per share, in multiple tranches. After these transactions, the filing shows the living trust holding 4,531,732 shares, and it also lists additional indirect holdings in several estate planning trusts and 1,452,739 shares held directly, with Jitendra disclaiming beneficial ownership of the trust-held shares except for any pecuniary interest.

Insights

Equity markets and insider-transactions analyst

Pre-planned trust sales by Astera Labs’ CEO, leaving a large remaining stake.

Astera Labs CEO and director Mohan Jitendra reported net open-market sales of 157,500 common shares on March 17, 2026. The transactions were executed by a living trust associated with him, not directly by Jitendra, and are classified as routine open-market sales.

A key detail is that these trades occurred automatically under a Rule 10b5-1 trading plan adopted on December 1, 2025, indicating they were pre-scheduled rather than opportunistic. After the sales, the living trust still holds 4,531,732 shares, and the filing lists additional indirect trust holdings plus 1,452,739 shares held directly.

This combination of a large remaining position and pre-planned status generally frames the activity as portfolio diversification or liquidity management rather than a strong directional signal on the company’s prospects. Subsequent company filings may provide further context on Jitendra’s overall ownership and any future trading plan activity.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Mohan Jitendra

(Last) (First) (Middle)

C/O ASTERA LABS, INC.

2345 NORTH FIRST STREET

(Street)

SAN JOSE CALIFORNIA 95131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Astera Labs, Inc. [ ALAB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Executive Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		8,754	D	$125.5575(2)	4,680,478	I	By Living Trust(3)
Common Stock	03/17/2026		S(1)		5,746	D	$126.6444(4)	4,674,732	I	By Living Trust(3)
Common Stock	03/17/2026		S(1)		3,624	D	$127.4731(5)	4,671,108	I	By Living Trust(3)
Common Stock	03/17/2026		S(1)		7,907	D	$128.6415(6)	4,663,201	I	By Living Trust(3)
Common Stock	03/17/2026		S(1)		11,120	D	$129.6162(7)	4,652,081	I	By Living Trust(3)
Common Stock	03/17/2026		S(1)		13,880	D	$130.741(8)	4,638,201	I	By Living Trust(3)
Common Stock	03/17/2026		S(1)		22,766	D	$131.6101(9)	4,615,435	I	By Living Trust(3)
Common Stock	03/17/2026		S(1)		43,289	D	$132.7214(10)	4,572,146	I	By Living Trust(3)
Common Stock	03/17/2026		S(1)		22,309	D	$133.6642(11)	4,549,837	I	By Living Trust(3)
Common Stock	03/17/2026		S(1)		18,105	D	$134.6738(12)	4,531,732	I	By Living Trust(3)
Common Stock								699,999	I	By Trust(13)
Common Stock								700,000	I	By 2021 Trust 1(14)
Common Stock								700,000	I	By 2021 Trust 2(15)
Common Stock								450,001	I	By 2022 Trust 1(16)
Common Stock								450,001	I	By 2022 Trust 2(17)
Common Stock								1,452,739	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The sales reported in this Form 4 occurred automatically pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 1, 2025.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.0700 to $126.0000, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. These shares are owned directly by a living trust (the "Living Trust"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.0800 to $127.0600, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.1100 to $128.0400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

6. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.1500 to $129.1300, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

7. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $129.1600 to $130.1500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

8. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $130.1600 to $131.1500, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

9. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $131.1600 to $132.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

10. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $132.1750 to $133.1700, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

11. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $133.1775 to $134.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

12. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $134.2000 to $135.1400, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the U.S. Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

13. These shares are owned directly by an estate planning trust (the "Trust"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

14. These shares are owned directly by an estate planning trust (the "2021 Trust 1"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

15. These shares are owned directly by an estate planning trust (the "2021 Trust 2"), of which the Reporting Person is a trustee. The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

16. These shares are owned directly by an estate planning trust (the "2022 Trust 1"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

17. These shares are owned directly by an estate planning trust (the "2022 Trust 2"). The Reporting Person disclaims beneficial ownership of these securities, except to the extent, if any, of his pecuniary interest therein, and the filing of this Form 4 is not an admission that the Reporting Person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose.

Remarks:

	/s/ Philip Mazzara, Attorney-in-Fact	03/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did Astera Labs (ALAB) disclose for its CEO?

Astera Labs disclosed that a living trust associated with CEO Mohan Jitendra sold 157,500 common shares. The sales occurred on March 17, 2026, as open-market transactions and were executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 1, 2025.

At what prices were the Astera Labs (ALAB) shares sold in this Form 4?

The reported sales used weighted-average prices between roughly $125 and $135 per share. Individual tranches show prices such as $125.5575, $126.6444, $127.4731 and up to $134.6738, reflecting multiple open-market transactions executed throughout March 17, 2026.

How many Astera Labs (ALAB) shares remain in the living trust after the CEO-related sales?

After the reported transactions, the living trust associated with CEO Mohan Jitendra holds 4,531,732 Astera Labs shares. This remaining stake indicates that, despite selling 157,500 shares, the trust continues to own a substantial position in the company’s common stock.

Were the Astera Labs (ALAB) insider sales part of a Rule 10b5-1 plan?

Yes, the filing states the sales occurred automatically under a Rule 10b5-1 trading plan. That plan was adopted by the reporting person on December 1, 2025, meaning the March 17, 2026 transactions were pre-scheduled rather than discretionary market-timing trades.

Does the Astera Labs (ALAB) CEO directly own shares after this Form 4 filing?

Yes, the Form 4 lists 1,452,739 Astera Labs shares held directly. In addition to this direct stake, the filing shows large indirect holdings through a living trust and several estate planning trusts, though beneficial ownership of those trust shares is disclaimed except for any pecuniary interest.

Who actually holds the Astera Labs (ALAB) shares that were sold in this Form 4?

The sold shares were held by a living trust associated with CEO Mohan Jitendra. The filing explains that the shares are owned directly by the living trust, with Jitendra as a trustee, and he disclaims beneficial ownership except to the extent of any pecuniary interest.